chandpura病毒在印度卷土重来:对诊断工具、抗病毒药物开发和公共卫生影响的见解。

IF 1.1 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Global Health Epidemiology and Genomics Pub Date : 2025-04-21 eCollection Date: 2025-01-01 DOI:10.1155/ghe3/1015031
Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Joel Chuku, Olajide Ojo, Petra Mariaria, Uthman Alao, Raolat Adenike Salami, Michael Oladunjoye
{"title":"chandpura病毒在印度卷土重来:对诊断工具、抗病毒药物开发和公共卫生影响的见解。","authors":"Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Joel Chuku, Olajide Ojo, Petra Mariaria, Uthman Alao, Raolat Adenike Salami, Michael Oladunjoye","doi":"10.1155/ghe3/1015031","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Chandipura virus (CHPV) is an emerging rhabdovirus primarily affecting pediatric populations in India, causing acute encephalitis syndrome (AES) with high mortality rates. First identified in 1965, CHPV has resurfaced in several outbreaks, the most recent being in 2024, with significant public health implications. The virus is transmitted primarily by sandflies, particularly <i>Phlebotomus</i> spp., and has been associated with a rapid progression of symptoms, leading to severe neurological damage and death. Despite advances in diagnostic techniques, no specific antiviral treatment or licensed vaccine currently exists. <b>Main Body of Abstract:</b> This manuscript reviews the latest findings on CHPV, focusing on diagnostic advancements, treatment strategies, and public health responses. Reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) have emerged as vital tools for rapid and accurate diagnosis, enabling the identification of CHPV in clinical and environmental samples. Antiviral therapies, such as ribavirin and favipiravir, have shown promise in vitro and preclinical models, but human trials are lacking. Additionally, the virus's unique epidemiology, including its reliance on sandfly transmission, complicates control efforts, particularly in resource-limited settings. The 2024 outbreak, with a case fatality ratio of over 30%, highlights the urgent need for improved surveillance, vector control measures, and public health interventions to curb the spread of CHPV. <b>Conclusion:</b> Despite considerable progress in diagnostics and experimental treatments, significant challenges remain in controlling CHPV outbreaks. The lack of specific antiviral therapies and vaccines continues to hinder effective management. Strengthened vector control strategies, advanced diagnostic infrastructure, and ongoing research into antiviral development are essential for mitigating the impact of CHPV in affected regions. International collaboration and sustained public health efforts will be crucial in preventing future outbreaks and reducing the disease burden.</p>","PeriodicalId":44052,"journal":{"name":"Global Health Epidemiology and Genomics","volume":"2025 ","pages":"1015031"},"PeriodicalIF":1.1000,"publicationDate":"2025-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037235/pdf/","citationCount":"0","resultStr":"{\"title\":\"Chandipura Virus Resurgence in India: Insights Into Diagnostic Tools, Antiviral Development, and Public Health Implications.\",\"authors\":\"Adewunmi Akingbola, Abiodun Adegbesan, Kolade Adegoke, Joel Chuku, Olajide Ojo, Petra Mariaria, Uthman Alao, Raolat Adenike Salami, Michael Oladunjoye\",\"doi\":\"10.1155/ghe3/1015031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Chandipura virus (CHPV) is an emerging rhabdovirus primarily affecting pediatric populations in India, causing acute encephalitis syndrome (AES) with high mortality rates. First identified in 1965, CHPV has resurfaced in several outbreaks, the most recent being in 2024, with significant public health implications. The virus is transmitted primarily by sandflies, particularly <i>Phlebotomus</i> spp., and has been associated with a rapid progression of symptoms, leading to severe neurological damage and death. Despite advances in diagnostic techniques, no specific antiviral treatment or licensed vaccine currently exists. <b>Main Body of Abstract:</b> This manuscript reviews the latest findings on CHPV, focusing on diagnostic advancements, treatment strategies, and public health responses. Reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) have emerged as vital tools for rapid and accurate diagnosis, enabling the identification of CHPV in clinical and environmental samples. Antiviral therapies, such as ribavirin and favipiravir, have shown promise in vitro and preclinical models, but human trials are lacking. Additionally, the virus's unique epidemiology, including its reliance on sandfly transmission, complicates control efforts, particularly in resource-limited settings. The 2024 outbreak, with a case fatality ratio of over 30%, highlights the urgent need for improved surveillance, vector control measures, and public health interventions to curb the spread of CHPV. <b>Conclusion:</b> Despite considerable progress in diagnostics and experimental treatments, significant challenges remain in controlling CHPV outbreaks. The lack of specific antiviral therapies and vaccines continues to hinder effective management. Strengthened vector control strategies, advanced diagnostic infrastructure, and ongoing research into antiviral development are essential for mitigating the impact of CHPV in affected regions. International collaboration and sustained public health efforts will be crucial in preventing future outbreaks and reducing the disease burden.</p>\",\"PeriodicalId\":44052,\"journal\":{\"name\":\"Global Health Epidemiology and Genomics\",\"volume\":\"2025 \",\"pages\":\"1015031\"},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2025-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12037235/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Health Epidemiology and Genomics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1155/ghe3/1015031\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Health Epidemiology and Genomics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ghe3/1015031","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

摘要

背景:昌迪普拉病毒(CHPV)是一种新兴的横纹病病毒,主要影响印度的儿科人群,引起急性脑炎综合征(AES),死亡率高。首次发现于1965年,CHPV在几次暴发中重新出现,最近一次是在2024年,具有重大的公共卫生影响。该病毒主要由白蛉,特别是白蛉传播,并与症状的迅速进展有关,导致严重的神经损伤和死亡。尽管诊断技术取得了进步,但目前还没有特定的抗病毒治疗方法或获得许可的疫苗。摘要:本文综述了CHPV的最新研究成果,重点介绍了诊断进展、治疗策略和公共卫生应对措施。逆转录聚合酶链反应(RT-PCR)和酶联免疫吸附测定(ELISA)已成为快速准确诊断的重要工具,能够在临床和环境样本中识别CHPV。抗病毒疗法,如利巴韦林和法匹拉韦,已经在体外和临床前模型中显示出希望,但缺乏人体试验。此外,该病毒独特的流行病学,包括依赖白蛉传播,使控制工作复杂化,特别是在资源有限的环境中。2024年的疫情病死率超过30%,突出表明迫切需要改善监测、病媒控制措施和公共卫生干预措施,以遏制CHPV的传播。结论:尽管在诊断和实验性治疗方面取得了相当大的进展,但在控制CHPV疫情方面仍存在重大挑战。缺乏特异性抗病毒疗法和疫苗继续阻碍有效管理。加强病媒控制战略、先进的诊断基础设施和正在进行的抗病毒药物开发研究对于减轻受影响地区的CHPV影响至关重要。国际合作和持续的公共卫生努力对于预防未来的疫情和减轻疾病负担至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Chandipura Virus Resurgence in India: Insights Into Diagnostic Tools, Antiviral Development, and Public Health Implications.

Background: Chandipura virus (CHPV) is an emerging rhabdovirus primarily affecting pediatric populations in India, causing acute encephalitis syndrome (AES) with high mortality rates. First identified in 1965, CHPV has resurfaced in several outbreaks, the most recent being in 2024, with significant public health implications. The virus is transmitted primarily by sandflies, particularly Phlebotomus spp., and has been associated with a rapid progression of symptoms, leading to severe neurological damage and death. Despite advances in diagnostic techniques, no specific antiviral treatment or licensed vaccine currently exists. Main Body of Abstract: This manuscript reviews the latest findings on CHPV, focusing on diagnostic advancements, treatment strategies, and public health responses. Reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunosorbent assay (ELISA) have emerged as vital tools for rapid and accurate diagnosis, enabling the identification of CHPV in clinical and environmental samples. Antiviral therapies, such as ribavirin and favipiravir, have shown promise in vitro and preclinical models, but human trials are lacking. Additionally, the virus's unique epidemiology, including its reliance on sandfly transmission, complicates control efforts, particularly in resource-limited settings. The 2024 outbreak, with a case fatality ratio of over 30%, highlights the urgent need for improved surveillance, vector control measures, and public health interventions to curb the spread of CHPV. Conclusion: Despite considerable progress in diagnostics and experimental treatments, significant challenges remain in controlling CHPV outbreaks. The lack of specific antiviral therapies and vaccines continues to hinder effective management. Strengthened vector control strategies, advanced diagnostic infrastructure, and ongoing research into antiviral development are essential for mitigating the impact of CHPV in affected regions. International collaboration and sustained public health efforts will be crucial in preventing future outbreaks and reducing the disease burden.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Global Health Epidemiology and Genomics
Global Health Epidemiology and Genomics PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
1.40
自引率
0.00%
发文量
10
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信